PDCD1 and neoplasm: Strecker et al. [104] evaluated the effectiveness of the tumor‐specific delivery of an anti‐PD‐1 immunoadhesin (aPD‐1) using a targeted adeno‐associated viral vector (AAV) in conjunction with receptor protein‐tyrosine kinase (HER2)‐specific NK‐92/5.28.z (anti‐HER2.CAR/NK‐92) cells as a component of a combination immunotherapy strategy.